Loading
When PSMA PET finds only a few spots after surgery, zap each spot with focused radiation and delay or avoid lifelong hormone therapy.
The idea is to use PSMA PET after prostate surgery to find the few sites of recurrence and treat each with stereotactic radiotherapy plus short-course androgen deprivation. The oligometastatic state is real in prostate cancer, the radiotherapy is ablative and cheap, and PSMA PET removes the staging blind spot that undermined older trials such as ORIOLE and STOMP. The hypothesis is better metastasis-free and ADT-free survival than systemic therapy alone, though whether it changes survival or merely postpones hormone therapy is unproven. The test is a randomised phase 3 with PSMA PET at baseline and progression and ctDNA as a stratifier; PEACE V/STORM and NRG GU011 are under way, so it is being tested at scale.
Shares Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial, A test to tell true oligometastatic disease from hidden widespread spread, Oligometastatic disease, Metastasis is understood least and studied last.
Shares Biochemical recurrence (BCR), Oligometastatic disease, Biochemical recurrence of prostate cancer, PSMA PET.
Shares A test to tell true oligometastatic disease from hidden widespread spread, Oligometastatic disease, Metastasis is understood least and studied last, SBRT / SABR (stereotactic radiotherapy).
Shares Biochemical recurrence (BCR), Oligometastatic disease, Biochemical recurrence of prostate cancer, SBRT / SABR (stereotactic radiotherapy).
Shares Oligometastatic disease, Metastasis is understood least and studied last, Prostate cancer.
Shares Biochemical recurrence of prostate cancer, PSMA PET, Prostate cancer roadmap: from Huggins and the discovery that a cancer can depend on a hormone, through the PSA epidemic and what it cost, the androgen receptor drugs, the DNA repair subset and PSMA, to a 2032 registry watch, Prostate cancer.
Shares Randomise the order of treatment, not only the drugs: a strategy platform for metastatic prostate cancer, PSMA PET, Prostate cancer roadmap: from Huggins and the discovery that a cancer can depend on a hormone, through the PSA epidemic and what it cost, the androgen receptor drugs, the DNA repair subset and PSMA, to a 2032 registry watch, Prostate cancer.
Shares Biochemical recurrence (BCR), Randomise the order of treatment, not only the drugs: a strategy platform for metastatic prostate cancer, Biochemical recurrence of prostate cancer, PSMA PET.